Psych MEQs / SAQs · Foundations — psychological and neuropsychological testing
Design a cognitive assessment pathway for complex presentations (MEQ)
FRANZCP-style MEQ on screens vs batteries, MoCA caveats, NP referral, schizophrenia cognition evidence, and communication.
On this page & tools
Target exams
Model answer
Reveal model answer
(i) Distinctions. Bedside screens (MoCA/MMSE/FAB) are brief triage tools. Formal neuropsychological assessment is hypothesis-driven multi-domain testing with norms, validity indices, and functional interpretation by trained examiners. Symptom rating scales (e.g. PHQ-9, PANSS) quantify psychiatric symptom constructs and do not replace domain-level cognitive profiling. Diagnosis and capacity remain clinical judgements informed by — not replaced by — scores.[1][4][7]
(ii) MoCA 22 interpretation. MoCA was validated as an MCI-oriented brief screen; scores around/below the commonly taught cut near 26 raise concern for cognitive impairment needing full assessment, but Carson et al. caution against universal cut-offs. A score of 22 is not a dementia diagnosis. Exclude delirium (CAM features: acute onset/fluctuation, inattention), depression effects, medications, sensory limits, language/education mismatch, sleep, substances, and suboptimal effort. Complete collateral, function (IADLs), and basic organic work-up as indicated.[1][2][3]
(iii) Formal NP referral. Refer when diagnostic uncertainty remains, progressive or atypical pattern, high-stakes functional decisions, or need for domain profile beyond screening. Specify: referral question (e.g. amnestic vs dysexecutive pattern; contribution of mood vs neurodegenerative disease), relevant history, medications, language, education, sensory issues, and request for validity assessment if inconsistency suspected.[7]
(iv) Schizophrenia cognition. Use MCCB (consensus trial battery with reliability/validity data) or BACS as a briefer validated alternative. Green’s synthesis shows neurocognitive deficits constrain community function more tightly than residual positive symptoms alone — justifying cognitive characterisation for vocational planning and remediation, not only antipsychotic optimisation.[4][5][6]
(v) Communication. Older adult: explain MoCA as a check of thinking skills, not a pass/fail intelligence test; share that low scores mean we look carefully for treatable causes and may arrange specialist testing; emphasise partnership. Schizophrenia patient: frame cognitive testing as identifying strengths and difficulties for work/rehab supports; normalise that many people with schizophrenia have thinking-speed or memory challenges independent of “being crazy”; offer written summary and follow-up.[1][4][6]
Common errors
Calling MoCA diagnostic of Alzheimer disease; skipping delirium; equating IQ with capacity; ignoring education/language; knowing MCCB name without Green functional rationale; jargon-heavy feedback without practical next steps.[1][2][3][6]
References
- [1]Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment J Am Geriatr Soc, 2005.PMID 15817019
- [2]Carson N, Leach L, Murphy KJ A re-examination of Montreal Cognitive Assessment (MoCA) cutoff scores Int J Geriatr Psychiatry, 2018.PMID 28731508
- [3]Inouye SK, van Dyck CH, Alessi CA, et al. Clarifying confusion: the confusion assessment method. A new method for detection of delirium Ann Intern Med, 1990.PMID 2240918
- [4]Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity Am J Psychiatry, 2008.PMID 18172019
- [5]Keefe RS, Goldberg TE, Harvey PD, et al. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery Schizophr Res, 2004.PMID 15099610
- [6]Green MF What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry, 1996.PMID 8610818
- [7]Sachdev PS, Blacker D, Blazer DG, et al. Classifying neurocognitive disorders: the DSM-5 approach Nat Rev Neurol, 2014.PMID 25266297